184 related articles for article (PubMed ID: 24102728)
1. Maintaining goal blood pressures after switching from olmesartan to other angiotensin receptor blockers.
Saseen JJ; Ghushchyan V; Kaila S; Allen RR; Nair KV
J Clin Hypertens (Greenwich); 2013 Dec; 15(12):888-92. PubMed ID: 24102728
[TBL] [Abstract][Full Text] [Related]
2. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.
Ram CV; Ramaswamy K; Qian C; Biskupiak J; Ryan A; Quah R; Russo PA
J Clin Hypertens (Greenwich); 2011 Nov; 13(11):801-12. PubMed ID: 22051424
[TBL] [Abstract][Full Text] [Related]
4. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Stumpe KO
Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.
Oparil S; Williams D; Chrysant SG; Marbury TC; Neutel J
J Clin Hypertens (Greenwich); 2001; 3(5):283-91, 318. PubMed ID: 11588406
[TBL] [Abstract][Full Text] [Related]
6. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension.
Giles TD; Oparil S; Silfani TN; Wang A; Walker JF
J Clin Hypertens (Greenwich); 2007 Mar; 9(3):187-95. PubMed ID: 17341994
[TBL] [Abstract][Full Text] [Related]
7. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
[TBL] [Abstract][Full Text] [Related]
8. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
[TBL] [Abstract][Full Text] [Related]
9. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
10. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive effects of olmesartan compared with other angiotensin receptor blockers: a meta-analysis.
Wang L; Zhao JW; Liu B; Shi D; Zou Z; Shi XY
Am J Cardiovasc Drugs; 2012 Oct; 12(5):335-44. PubMed ID: 22920046
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K
Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596
[TBL] [Abstract][Full Text] [Related]
14. Irbesartan substitution for valsartan or losartan in treating hypertension.
Graham MR; Allcock NM
Ann Pharmacother; 2002 Dec; 36(12):1840-4. PubMed ID: 12452741
[TBL] [Abstract][Full Text] [Related]
15. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy.
Fogari R; Zoppi A; Mugellini A; Preti P; Destro M; Rinaldi A; Derosa G
Adv Ther; 2006; 23(5):680-95. PubMed ID: 17142202
[TBL] [Abstract][Full Text] [Related]
16. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
[TBL] [Abstract][Full Text] [Related]
17. Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Belsey JD
Curr Med Res Opin; 2008 Feb; 24(2):581-9. PubMed ID: 18198012
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
[TBL] [Abstract][Full Text] [Related]
19. Olmesartan/amlodipine: a review of its use in the management of hypertension.
Kreutz R
Vasc Health Risk Manag; 2011; 7():183-92. PubMed ID: 21490944
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Everett BM; Glynn RJ; Danielson E; Ridker PM;
Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
